عرض بسيط للتسجيلة

المؤلفShurrab, Farah M.
المؤلفAl-Sadeq, Duaa W.
المؤلفAbou-Saleh, Haissam
المؤلفAl-Dewik, Nader
المؤلفElsharafi, Amira E.
المؤلفHamaydeh, Fatima M.
المؤلفAbo Halawa, Bushra Y.
المؤلفJamaleddin, Tala M.
المؤلفAbdul Hameed, Huda M.
المؤلفNizamuddin, Parveen B.
المؤلفAmanullah, Fathima Humaira
المؤلفDaas, Hanin I.
المؤلفAbu-Raddad, Laith J.
المؤلفNasrallah, Gheyath K.
تاريخ الإتاحة2022-05-11T07:08:33Z
تاريخ النشر2022-02-01
اسم المنشورVaccines
المعرّفhttp://dx.doi.org/10.3390/vaccines10020191
الاقتباسShurrab, F.M.; Al-Sadeq, D.W.; Abou-Saleh, H.; Al-Dewik, N.; Elsharafi, A.E.; Hamaydeh, F.M.; Halawa, B.Y.A.; Jamaleddin, T.M.; Hameed, H.M.A.; Nizamuddin, P.B.; Amanullah, F.H.; Daas, H.I.; Abu-Raddad, L.J.; Nasrallah, G.K. Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study. Vaccines 2022, 10, 191. https://doi.org/10.3390/vaccines10020191
معرّف المصادر الموحدhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85124042840&origin=inward
معرّف المصادر الموحدhttp://hdl.handle.net/10576/30830
الملخصThe currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was shown that the magnitude of the neutralizing antibody (NAbs) response correlates with the degree of protection. However, the difference between the immune response in naïve mRNA-vaccinated and previously infected (PI) individuals is not well studied. We investigated the level of NAbs in naïve and PI individuals after 1 to 26 (median = 6) weeks of the second dose of BNT162b2 or mRNA-1273 vaccination. The naïve mRNA-1273 vaccinated group (n = 68) generated significantly higher (~2-fold, p ≤ 0.001) NAbs than the naïve BNT162b2 (n = 358) group. The P -vaccinated group (n = 42) generated significantly higher (~3-fold; p ≤ 0.001) NAbs levels than the naïve-BNT162b2 (n = 426). Additionally, the older age groups produced a significantly higher levels of antibodies than the young age group (>30) (p = 0.0007). Our results showed that mRNA-1273 generated a higher NAbs response than the BNT162b2 vaccine, and the PI group generated the highest level of NAbs response regardless of the type of vaccine.
راعي المشروعThis work was made possible by grant number UREP28-173-3-057 from the Qatar National Research Fund (a member of Qatar Foundation). The statements made herein are solely the responsibility of the authors.
اللغةen
الناشرMDPI
الموضوعModerna-mRNA-1273
Neutralizing antibodies
Pfizer-BNT162b2
SARS-CoV-2
Vaccine
العنوانAssessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study
النوعReport
رقم العدد2
رقم المجلد10
ESSN2076-393X
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة